Education
About Us
Working with TipRanks
Follow Us
Haemonetics Corp. (HAE)
NYSE:HAE
Total Valuation
Haemonetics has a market cap or net worth of $3.63B. The enterprise value is $4.69B.
Market Cap$3.63B
Enterprise Value$4.69B
Share Statistics
Haemonetics has 48,036,995 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding48,036,995
Owned by Insiders1.18%
Owned by Institutions0.20%
Financial Efficiency
Haemonetics’s return on equity (ROE) is 0.20 and return on invested capital (ROIC) is 8.06%.
Return on Equity (ROE)0.20
Return on Assets (ROA)0.07
Return on Invested Capital (ROIC)8.06%
Return on Capital Employed (ROCE)0.12
Revenue Per Employee372.11K
Profits Per Employee45.85K
Employee Count3,657
Asset Turnover0.56
Inventory Turnover1.68
Valuation Ratios
The current PE Ratio of Haemonetics is 18.97. Haemonetics’s PEG ratio is 3.36.
PE Ratio18.97
PS Ratio0.00
PB Ratio6.75
Price to Fair Value3.87
Price to FCF111.81
Price to Operating Cash Flow28.30
PEG Ratio3.36
Income Statement
In the last 12 months, Haemonetics had revenue of 1.36B and earned 167.68M in profits. Earnings per share was 3.31.
Revenue1.36B
Gross Profit748.96M
Operating Income221.82M
Pretax Income212.07M
Net Income167.68M
EBITDA221.82M
Earnings Per Share (EPS)3.31
Cash Flow
In the last 12 months, operating cash flow was 181.72M and capital expenditures -39.28M, giving a free cash flow of 142.45M billion.
Operating Cash Flow181.72M
Free Cash Flow142.45M
Free Cash Flow per Share2.97
Dividends & Yields
Haemonetics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.90
52-Week Price Change-16.27%
50-Day Moving Average70.24
200-Day Moving Average72.01
Relative Strength Index (RSI)58.32
Average Volume (3m)546.33K
Important Dates
Haemonetics upcoming earnings date is Aug 7, 2025, Before Open (Confirmed).
Last Earnings DateMay 8, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date―
Financial Position
Haemonetics as a current ratio of 1.62, with Debt / Equity ratio of 52.42%
Current Ratio1.62
Quick Ratio0.99
Debt to Market Cap0.10
Net Debt to EBITDA-0.01
Interest Coverage Ratio-22.76
Taxes
In the past 12 months, Haemonetics has paid 44.39M in taxes.
Income Tax44.39M
Effective Tax Rate0.21
Enterprise Valuation
Haemonetics EV to EBITDA ratio is 14.32, with an EV/FCF ratio of 22.30.
EV to Sales2.33
EV to EBITDA14.32
EV to Free Cash Flow22.30
EV to Operating Cash Flow17.48
Balance Sheet
Haemonetics has $306.76M in cash and marketable securities with $1.22B in debt, giving a net cash position of $918.02M billion.
Cash & Marketable Securities$306.76M
Total Debt$1.22B
Net Cash$918.02M
Net Cash Per Share$19.11
Tangible Book Value Per Share-$4.75
Margins
Gross margin is 43.15%, with operating margin of 16.30%, and net profit margin of 12.32%.
Gross Margin43.15%
Operating Margin16.30%
Pretax Margin15.58%
Net Profit Margin12.32%
EBITDA Margin16.30%
EBIT Margin0.00%
Analyst Forecast
The average price target for Haemonetics is $92.29, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$92.29
Price Target Upside22.21% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast3.95%
EPS Growth Forecast44.09%